King Pharmaceuticals' (KG) fourth quarter earnings of $0.23 were a penny shy of the Zacks Consensus Estimate.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
KING PHARMACEUTICALS (KG)
King Pharmaceuticals, Inc. is the world’s 39th-largest pharmaceutical company. It provides branded prescription pharmaceutical products worldwide It primarily offers branded prescription products for primary care physicians, neurologists, orthopedic surgeons, hospitals, internal medicine physicians, allergists, pediatricians, and pain specialists. Some brands include Altace for heart attack prevention; Levoxyl for hypothyroidism; Sonata for sleeping; and Skelaxin, a muscle relaxant.
King Pharmaceuticals (KG) is part of Business Exchange, suggested by
Ginny Moore.
This topic contains
133 news
and
95 blog
items.
Read updated news, blogs, and resources about King Pharmaceuticals (KG). Find user-submitted articles and reactions on King Pharmaceuticals (KG) from
like-minded professionals.
Blogs
Please add new articles to this topic
King Pharmaceuticals (NYSE: KG) opened at $9.55. So far today, the stock has hit a low of $9.53 and a high of $9.62.
Submission Targeted for Early 2011...
King Pharmaceuticals, Inc (KG) is scheduled to report their first quarter 2010 results on Thursday, May 6.[More...]
BRISTOL, TN and PALATINE, IL--(Marketwire - May 03, 2010) - King Pharmaceuticals, Inc. (NYSE: KG) and Acura...
Marketwire - April 28, 2010) - King Pharmaceuticals, Inc. (NYSE: KG) reported today...
...baltimoresun.com (US) [OxyContin (drug) ...] ...
Marketwire - April 28, 2010) - ��King Pharmaceuticals, Inc.
Reuters -- U.S. regulators questioned if an experimental pain drug from King Pharmaceuticals (KG.N) and Acura...
Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) and King Pharmaceuticals��, Inc. (NYSE: KG) announced that the U.S. Food and.
DURECT Corporation announced Wednesday that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to...
DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to...
CUPERTINO, Calif., April 7 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that its licensee, King...
Neil Carvin submits: This post describes our model of King Pharmaceuticals' (NYSE: KG) Income Statement for the first...
King Pharmaceuticals (KG) was upgraded today by analysts at EVA Dimensions, LLC and the stock is now at $11.86, down $0.
To correct any false or misleading impression you may have gained from the news releases, King is providing you with...
DURECT Corporation (Nasdaq: DRRX) announced that its licensee, King Pharmaceuticals (NYSE: KG), has begun a Phase IIb...
...e1c6c3/analysis_of_king_p) has announced the addition of the "Analysis of King Pharmaceuticals" company...
...was made by the Alpharma subsidiary of King Pharmaceuticals, as reported by Reuters: Alpharma Inc, a unit of King...
BRISTOL, TN (MARKET WIRE) King Pharmaceuticals, Inc. (NYSE: KG) today announced plans to...
Marketwire - March 19, 2010) - King Pharmaceuticals, Inc. (NYSE: KG) today...
King Pharmaceuticals (KG) was upgraded today by analysts at Thomson Financial - Gradient and the stock is now at $12.
BRISTOL, TN--(HSMN NewsFeed) - King Pharmaceuticals, Inc. (NYSE:KG ) today announced that its subsidiaries, Alpharma...
2010 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) and King Pharmaceuticals, Inc. (NYSE:KG) today...
Top Sources: King Pharmaceuticals (KG)
- Finance, Investments n Trading
- BioSpace.com Featured News
- Cafepharma Message Boards
- 10Q Detective
- BlogNetNews.com » Tennessee
- M2 PressWIRE: Latest Headlines
- MarketIntelligenceCenter.com
- optionMONSTER News
- Pharma Analysis RSS | BNET Industries
- Latest articles from PRWeek US News
Most Active Users in this Topic
No user contributions
account